B-cell proliferation characteristics and monitoring significance under the modified reduced-dose rituximab regimen for NMOSD: A real-world case series study

医学 美罗华 CD19 养生 视神经脊髓炎 多发性硬化 B细胞 内科学 扩大残疾状况量表 流式细胞术 免疫学 胃肠病学 抗体
作者
Shugang Cao,Xiaoyuan Wang,Xiaopei Ji,Jingluan Tian,Yunfei Zhu,Xin Wang,Yanzheng Gu,Xiaoyu Duan,Xinyi Xiao,Qi Fang,Xueguang Zhang,Qun Xue
出处
期刊:Multiple sclerosis and related disorders [Elsevier BV]
卷期号:70: 104524-104524 被引量:4
标识
DOI:10.1016/j.msard.2023.104524
摘要

To explore the B-cell proliferation characteristics and monitoring significance under the modified reduced-dose rituximab (mRTX) regimen for neuromyelitis optica spectrum disorder (NMOSD).NMOSD patients treated with mRTX were recruited, and the percentages of total CD19+ B cells and CD27+ memory B cells were dynamically detected by flow cytometry. The annualized relapse rate (ARR) and expanded disability status scale (EDSS) scores were compared before and after mRTX treatment, and the differences in B-cell values were compared between groups.A total of 34 patients with NMOSD were ultimately enrolled. The EDSS score decreased from 2.5 (1.5, 3.0) to 1.3 (1.0, 2.0), and the ARR decreased from 1.0 (0, 2.0) to 0 (0, 0) (p < 0.001). Relapses occurred in 6 patients, with total CD19+ B-cell percentages of 3.25% (2.7%, 3.7%) and CD27+ memory B-cell percentages of 0.3% (0.2%, 0.3%) at initial relapse. Twenty-eight patients (82.4%) remained relapse-free with 84 doses of mRTX. Before 56 repeated doses, the total CD19+ B cells and CD27+ memory B cells were 4.00% (3.14%, 5.32%) and 0.26% (0.17%, 0.40%), respectively. The mean dosing interval was 9.2 months. Both total CD19+ B cells and CD27+ memory B cells proliferated over time after mRTX use, with significantly faster proliferation rates in the later stages. In 28 relapse-free patients, the mean time to reach 1% for total CD19+ B cells was 210 days, and the mean time to reach 3% was 240 days, with the mean interval from 1% to 3% of 65 days. Twenty-five relapse-free patients had no significant differences in maximum, minimum, and mean B-cell values compared to those of 6 patients with relapse.The high rate of B-cell proliferation under the mRTX regimen indicates that closer dynamic B-cell monitoring is required to guide repeated mRTX dosing. Sustained depletion of total CD19+ B cells targeting < 3% of lymphocytes may be feasible, enabling extended dosing intervals.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Tqun完成签到,获得积分10
刚刚
you完成签到 ,获得积分10
1秒前
lfy完成签到,获得积分10
1秒前
小毛竹完成签到 ,获得积分10
5秒前
DW的应助被WinStar采纳,获得10
5秒前
智文完成签到 ,获得积分10
7秒前
8秒前
从容棉花糖完成签到,获得积分10
9秒前
Akim的应助被俏皮诺言采纳,获得10
11秒前
junjun2011完成签到 ,获得积分10
11秒前
烟花弥漫完成签到 ,获得积分10
13秒前
明朗完成签到 ,获得积分0
14秒前
about发布了新的文献求助10
14秒前
默默白桃完成签到 ,获得积分10
16秒前
我爱自由民权完成签到,获得积分10
18秒前
阳光雅蕊完成签到,获得积分10
18秒前
hugefrog完成签到,获得积分10
20秒前
wxf666完成签到 ,获得积分10
20秒前
HelloBOB完成签到 ,获得积分10
22秒前
PORCO完成签到,获得积分10
27秒前
英勇雅琴完成签到 ,获得积分10
27秒前
dingo完成签到,获得积分10
30秒前
阿南完成签到 ,获得积分0
31秒前
朴素傲松完成签到,获得积分10
31秒前
追寻微笑完成签到 ,获得积分10
32秒前
taotao完成签到 ,获得积分10
32秒前
zilicai的应助被十二采纳,获得20
32秒前
duktig完成签到 ,获得积分10
33秒前
hooqueen完成签到 ,获得积分10
33秒前
about完成签到,获得积分10
34秒前
韩寒123完成签到,获得积分10
35秒前
特特特特特完成签到,获得积分10
37秒前
bobinson完成签到,获得积分10
37秒前
乐观的星月完成签到 ,获得积分0
41秒前
Hello的应助被liugm采纳,获得10
43秒前
小菀儿完成签到 ,获得积分10
44秒前
Royzeng完成签到 ,获得积分10
48秒前
止咳宝完成签到,获得积分10
48秒前
科研通AI6.3的应助被单身的紊采纳,获得10
50秒前
JonyJie完成签到,获得积分10
50秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190389
求助须知:如何正确求助?哪些是违规求助? 9577468
关于积分的说明 21852623
捐赠科研通 7789041
什么是DOI,文献DOI怎么找? 3436369
关于科研通互助平台的介绍 2560180
邀请新用户注册赠送积分活动 2482995